Select Solid Tumor Types

Type N TP TN FP FN Ref # Positive
Predictive
Accuracy		 Negative
Predictive
Accuracy		 False
Positive %		 False
Negative %
Breast 47 31 13 3 0 1 91.2% 100.0% 6.4% 0.0%
Breast 29 17 5 4 2 2 81.0% 71.4% 13.8% 6.9%
Breast 17 9 6 1 1 3 90.0% 85.7% 5.9% 5.9%
Breast 85 56 10 17 0 4 76.7% 100.00% 20.0% 0.0%
Breast 4 2 2 0 0 5 100.0% 100.0% 0.0% 0.0%
Breast 12 6 4 0 2 20 100.0% 66.7% 0.0% 16.7%
Breast Total 194 121 40 25 5   82.9% 88.9% 12.9% 2.6%
Colon 16 3 13 0 0 6 100.0% 100.0% 0.0% 0.0%
Colon 37 5 29 2 1 7 71.4% 96.7% 5.4% 2.7%
Colon 1 0 1 0 0 5 0.0% 100.0% 0.0% 0.0%
Colon Total 54 8 43 2 1   80.0% 97.7% 3.7% 1.9%
NSCLC 8 5 2 1 0 8 83.3% 100.0% 12.5% 0.0%
NSCLC 6 0 6 0 0 9 100.0% 100.0% 0.0% 0.0%
NSCLC 8 0 8 0 0 5 100.0% 100.0% 0.0% 0.0%
NSCLC 25 7 11 5 2 10 58.3% 84.6% 20.0% 8.0%
NSCLC Total 47 12 27 6 2   84.4% 93.1% 12.8% 4.3%
GYN 72 31 27 13 1 1 70.5% 96.4% 18.1% 1.4%
GYN 22 6 12 4 0 11 60.0% 100.0% 18.2% 0.0%
GYN 20 3 14 3 0 12 50.0% 100.0% 15.0% 0.0%
GYN 38 19 8 10 1 13 65.5% 88.9% 26.3% 2.6%
GYN 15 7 6 1 1 14 87.5% 85.7% 6.7% 6.7%
GYN 25 9 9 6 1 15 60.0% 90.0% 24.0% 4.0%
GYN 31 23 6 0 2 16 100.0% 75.0% 0.0% 6.5%
GYN 65 45 12 3 5 17 93.8% 70.6% 4.6% 7.7%
GYN 37 11 17 6 3 18 64.7% 85.0% 16.2% 8.1%
GYN 3 1 2 0 0 5 100.0% 100.0% 0.0% 0.0%
GYN 17 9 3 3 2 21 75.0% 60.0% 17.6% 11.8%
GYN Total 345 164 116 49 16   77.0% 87.9% 14.2% 4.6%
SCLC 1 1 0 0 0 19 100.0% 0.0% 0.0% 0.0%
SCLC 8 2 4 0 2 9 100.0% 66.7% 0.0% 25.0%
SCLC 10 0 7 3 0 5 0.0% 100.0% 30.0% 0.0%
SCLC 8 8 0 0 0 22 100.0% 0.0% 0.0% 0.0%
SCLC Total 27 11 11 3 2   78.6% 84.6% 15.8% 10.5%
Grand Total 667 316 237 85 26   78.8% 90.1% 12.7% 3.9%
  1. Blackman KE, Fingert HJ, Fuller AF, Meitner PA. The Fluorescent Cytoprint Assay in gynecologic malignancies and breast cancer: Methodology and results. In: Koechli OR, Sevin B-U, Haller U, eds. Chemosensitivity testing in gynecologic malignancies and breast cancer. Basel: Karger, 1994: 53-64.
  2. Cree IA, Kurbacher CM, Untch M., et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996: 7:630-635.
  3. Koechli OR, Avner BP, Sevin B-U, et al. Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing: a report on the first results. J. Surg Oncol 1993; 54: 119-125.
  4. Xu JM, Song ST, Tang ZM, et al. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 1999; 53: 77-85.
  5. Weisenthal LM, Marsden JA, Dill PL. Macaluso CK. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983; 43: 749-757.
  6. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 305-311.
  7. Imai S. Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer. Gan To Kagaku Ryoho 1999; 26:1289-1293
  8. Leone LA, Meitner PA, Myers TJ, et al. Predictive value of the fluorescent cytoprint assay (FCA): A retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy. Cancer Invest 1991; 9: 491.
  9. Smit EF, De Vries EGE, Meijer C, Mulder NH, Postmus PE. Limitations of the fast green assay for chemosensitivity testing in human lung cancer. Chest 1991; 100:1358-1363.
  10. Wilbur DW, Camacho ES, Hilliard DA, Dill PL, Weisenthal LM. Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br J Cancer 1992; 65: 27-32.
  11. Carstensen H, Tholander B. Chemosensitivity of ovarian carcinoma: In vitro/in vivo correlations using the dye exclusion assay of Weisenthal (meeting abstract). Proceedings: 3rd European Conference on Clinical Oncology 1985; Stockholm: p. 206.
  12. Ng TY, Ngan HY, Cheng DKL, Wong LC. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples. Gynec Oncol 2000; 76: 405-408.
  13. Konecny G, Crohns C, Pegram M, et al. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynec Oncol 2000; 77: 258-263.
  14. Ohie S. Udagawa Y, Kozu A, et al. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with Cisplatin, Doxorubicin and Cyclophosphamide. Anticancer Res 2000; 20: 2049-2054.
  15. Sargent J, Elgie A, Taylor CG, Wilson J, Alton P, Hill JG. The identification of drug resistance in ovarian cancer and breast cancer; application of the MTT assay. In: Koechli OR, Sevin B-U, Haller U, eds. Chemosensitivity testing in gynecologic malignancies and breast cancer. Basel: Karger, 1994: 64-75.
  16. Sevin B-U, Perras JP, Averette HE, Donato DM, Penalver M. Chemosensitivity testing in ovarian cancer. Cancer 1993; 71(Suppl): 1613-1620.
  17. Sevin BU, Perras JP, Koechli OR. Current status and future directions of chemosensitivity testing. In: Koechli OR, Sevin BU, Haller U, eds. Chemosensitivity testing in gynecologic malignancies and breast cancer. Basel: Karger, 1994: 179-194.
  18. Taylor CG, Sargent JM, Elgie AW, et al. The clinical relevance of chemosensitivity testing in ovarian cancer. Cancer Detect Prev 1998; 22: 305-312.
  19. Beksac M, Kansu E, Kars A, Ibrahimoglu Z, Firat D. A rapid drug sensitivity assay for neoplasmatic cells. Med Oncol Tumor Pharmacother 1988; 5: 253-257.
  20. Nagourney RA, Link JS, Blitzer, JB, Forsthoff C, et al. Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients. J Clin Onc, 2000; 18: 2245-2249.
  21. Nagourney RA, Brewer CA, Radecki S, et al. A Phase II Trial of Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer patients. Gyn Onc 2003, 88, 35-39.
  22. Cortazar P, Gazdar AF, Woods E, Russell E, Steinberg SM, Williams J, Ihde DC, Johnson E. Survival of Patients with Limited-Stage Small Cell Lung Cancer Treated with Individualized Chemotherapy Selected by in Vitro Drug Sensitivity Testing. Clin Canc Res 1997; 3:741-747.